Wellness, PsychologicalNCT06246539

Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness

A study testing VR mindfulness in people with Wellness, Psychological, run by University of Massachusetts, Worcester at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

Who is it for?: Any ageHealthy volunteers can take part
Conditions the study is for: Wellness, Psychological
What is being tested?: VR mindfulness
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 32 participants
Where: 1 siteUnited States
Study dates: 1 Oct 2026to 31 Jul 2028
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
All sexes
Healthy volunteers accepted
Child, Adult, Older adult

Who may be able to join

physician or APP employed by the Medical Group

Who cannot join

Not willing to receive 2 texts per week

Trial locations and contacts

1 site in 1 country.

United States1 site

UMassMemorial Health Care
Worcester, Massachusetts, 01655-0002

Other trials in United States

About this study

Burnout shares symptoms with anxiety and depression. While there is no single intervention for burnout, there are validated interventions (which are amenable to virtual reality (VR)) for anxiety and depression. UMassMemorial data from the Professional Well-Being Academic Consortium show that MD burnout and distress has increased since 2020. The investigators believe providing clinicians with a unique tool (VR) will be a feasible and efficacious way to tackle distress. It is known that only 1% of our MDs have done mindfulness training but nearly 50% are interested in doing so. Therefore, a self-administrable, interactive mindfulness program delivered over VR has great potential to reach clinicians who want to practice a more active form of mindfulness at a time convenient to them. The results of the study will provide preliminary evidence to determine if a take-home VR mindfulness program decreases clinician stress.

Read the detailed description

Cohorts 1 will be the intervention group Cohorts 2 will be the controls. Study endpoints include results from the following questionnaires:

PROMIS - Short Form Anxiety (8 questions)
PROMIS - Short Form Depression (8 questions)
Perceived Stress Scale (10 questions)
Connor-Davidson Brief Resilience Scale (10 questions)
System Usability Scale (10 questions)

The intervention is a 12-week mindfulness-based VR intervention.

Cohort 1 will complete the questionnaires 1-4 at baseline (just before the intervention). They will be sent twice weekly reminders to use the VR for the duration of the 12-week intervention. After 12 weeks Cohort 1 will retake questionnaires 1-4 and take questionnaire 5, while Cohort 2 will then take questionnaires 1-4 and be provided the VR headsets. After another 12 weeks, Cohort 1 will take questionnaires 1-4 and be done with the study, while Cohort 2 will take questionnaires 1-5. After 12 more weeks, Cohort 2 will take questionnaires 1-4 and be done with the study.

Conditions: Wellness, Psychological
Being tested: VR mindfulness
Medical subject headings: Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

VR mindfulnessBehavioural
VR-based mindfulness

Study groups in NCT06246539
Study group	Role	What they receive
Intervention - VR Mindfulness	Experimental	The intervention group will be given the VR headset for their unrestricted use over the 12 week intervention period. The VR headset is exceptionally easy and intuitive to use. Each participant will have the choice of 20 "locations" in which to use the mindfulness-based program. Each of the 20 locations/programs are different. They range in length from 5 minutes (introductory) to 20 minutes. Receives: Behavioral: VR mindfulness
Control	No intervention	The control arm will not have any intervention. However, at the conclusion of the study, all participants from the Control group will be given the VR intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

PROMIS - anxiety
PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
PROMIS - anxiety
PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
PROMIS - Depression
PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
PROMIS - Depression
PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
Resiliency
Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
Resiliency
Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
Stress scale
Perceived Stress Score. Scores of 0-40; Higher score is worse.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
Stress scale
Perceived Stress Score. Scores of 0-40; Higher score is worse.
Measured: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
Usability
Usability scale. Scores of 10-50; Higher score is better.
Measured: after 12 weeks we will dertermine the usability of the VR intervention in the intervention group

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Oct 202631 Jul 2028

First posted7 Feb 2024
Study start1 Oct 2026
Primary completion1 Jan 2028 (estimated)
Study completion31 Jul 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Wellness, PsychologicalStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 32 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06246539
Sponsor's protocol ID: 00001606
Status last verified: Oct 2026
First submitted: 30 Jan 2024
Last updated: 21 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
A Hybrid Effectiveness-Implementation and Cost-Utility Evaluation of a Support Programme for Informal Carers of People With Dementia in Primary Care (EsCuidar2)
Quality of Life
Active, not recruitingObservational study
Gulf Long-Term Follow-Up Study
Cardiovascular Disease, Hematologic Diseases
Not yet recruiting
Supporting Health and Empowerment Through Contingency Management and Affect Regulation
HIV Risk
Not yet recruiting
Pilot Study to Co-create and Implement a Multicomponent Intervention to Reduce Mental Health Stigma in Primary Care
Mental Health, Stigma of Mental Illness
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health

All Wellness, Psychological trials

Study at a glance

From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness
ClinicalTrials.gov ID: NCT06246539
Acronym / sponsor ID: 00001606
Conditions: Wellness, Psychological
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 32 participants (estimated)
Lead sponsor: University of Massachusetts, WorcesterUniversity, hospital or other
Study start: 1 Oct 2026 (actual)
Primary completion: 1 Jan 2028 (estimated)
Study completion: 31 Jul 2028 (estimated)
First posted: 7 Feb 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Cohorts 1 will be the intervention group Cohorts 2 will be the controls. Study endpoints include results from the following questionnaires:

PROMIS - Short Form Anxiety (8 questions)
PROMIS - Short Form Depression (8 questions)
Perceived Stress Scale (10 questions)
Connor-Davidson Brief Resilience Scale (10 questions)
System Usability Scale (10 questions)

The intervention is a 12-week mindfulness-based VR intervention.

Study design

Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Intervention - VR Mindfulness	Experimental	Behavioral: VR mindfulnessThe intervention group will be given the VR headset for their unrestricted use over the 12 week intervention period. The VR headset is exceptionally easy and intuitive to use. Each participant will have the choice of 20 "locations" in which to use the mindfulness-based program. Each of the 20 locations/programs are different. They range in length from 5 minutes (introductory) to 20 minutes.
Control	No intervention	–The control arm will not have any intervention. However, at the conclusion of the study, all participants from the Control group will be given the VR intervention

Who may qualify

Sex: All
Healthy volunteers: Accepted
Age groups: Child, Adult, Older adult

Key inclusion criteria (1 listed)

physician or APP employed by the Medical Group

Key exclusion criteria (1 listed)

Not willing to receive 2 texts per week

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
VR mindfulnessVR-based mindfulness	Behavioural	Intervention - VR Mindfulness

Primary outcome

PROMIS - anxiety
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.
PROMIS - anxiety
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.
PROMIS - Depression
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.
PROMIS - Depression
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.
Resiliency
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.
Resiliency
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.
Stress scale
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.
Perceived Stress Score. Scores of 0-40; Higher score is worse.
Stress scale
Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.
Perceived Stress Score. Scores of 0-40; Higher score is worse.
Usability
Time frame: after 12 weeks we will dertermine the usability of the VR intervention in the intervention group
Usability scale. Scores of 10-50; Higher score is better.

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Individual participant dataSharing planned: No

Related trials for Wellness, Psychological

Not yet recruiting
A Hybrid Effectiveness-Implementation and Cost-Utility Evaluation of a Support Programme for Informal Carers of People With Dementia in Primary Care (EsCuidar2)
Quality of Life
Active, not recruitingObservational study
Gulf Long-Term Follow-Up Study
Cardiovascular Disease, Hematologic Diseases
Not yet recruiting
Supporting Health and Empowerment Through Contingency Management and Affect Regulation
HIV Risk
Not yet recruiting
Pilot Study to Co-create and Implement a Multicomponent Intervention to Reduce Mental Health Stigma in Primary Care
Mental Health, Stigma of Mental Illness
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Steven Bird, MD principal investigator

University of Massachusetts, Worcester

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing VR mindfulness in people with Wellness, Psychological, run by University of Massachusetts, Worcester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PROMIS - anxiety (time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06246539.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.